FDA Breast Cancer Patient Meeting Likely To Examine Differences Between Early-Stage and Metastatic Experiences
This article was originally published in RPM Report
Executive Summary
In April, FDA’s patient focused drug development initiative will look at one of the most emotionally and politically fraught areas of advocacy: breast cancer. Here’s a look at what the agency is likely to hear.
You may also be interested in...
FDA Looking To Patient Advocates To Answer Benefit-Risk Questions
FDA’s clinical review teams are starting to approve novel drugs and biologics using a new structured benefit-risk framework developed under PDUFA V. Those assessments ask reviewers to think more broadly about the disease and how a new treatment might fit into the current treatment model. But many reviewers don’t have that information. And that, FDA says, is where patient advocates come in.
FDA-CMS Parallel Review Pilot Will Be Extended; Drugs Not The Focus
CMS remains open to the idea of using parallel review (or, less formal parallel advice) for prescription drugs, but the current and future focus of the pilot program is likely to stay on devices and diagnostics.
Personalized Medicine Meets Payment Policy: MEDCAC Has “Low Confidence” In Most Cancer Tests
Genomic screening of tumor types may be the cutting edge in cancer treatment and a central component of the President’s vision for personalized medicine. But how much evidence is necessary to make insurance coverage for testing routine?